Alpha lipoic acid efficacy in burning mouth syndrome: a controlled clinical trial by Palacios Sánchez, Begoña et al.
Med Oral Patol Oral Cir Bucal. 2015 Jul 1;20 (4):e435-40.                                                                                                                                       Eficacy of ala in burning mouth syndrome: A RCT
e435
Journal section: Oral Medicine and Pathology
Publication Types: Research
Alpha lipoic acid efficacy in burning mouth syndrome. 
A controlled clinical trial
Begoña Palacios-Sánchez 1, Luis-Alberto Moreno-López 2, Rocío Cerero-Lapiedra 1, Silvia Llamas-Martínez 1, 
Germán Esparza-Gómez 1 
1 DMD, PhD. MD, PhD. DMD, PhD. MD, PhD. Departamento de Medicina y Cirugía Bucofacial, Universidad Complutense de 
Madrid. Madrid. Spain
2 DMD, PhD Unidad de Medicina y Cirugía Oral. GAP Toledo. SESCAM. Toledo. Spain
Correspondence:
LAML. Centro de Salud Buenavista
Av Irlanda s/n
45003 Toledo, Spain 
lamoreno@sescam.jccm.es
Received: 06/10/2014
Accepted: 14/03/2015
Abstract
Background: A double-blind placebo-controlled trial was conducted in order to evaluate the efficacy of alpha 
lipoic acid (ALA) and determine the statistical significance of the outcome variables. Burning mouth syndrome 
(BMS) is defined as an oral burning sensation in the absence of clinical signs which could justify the syndrome. 
Recent studies suggest the existence of neurological factors as a possible cause of the disease. 
Material and Methods: 60 patients with BMS, in two groups: case group with 600 mg/day and placebo as control 
group; with follow up of 2 months. 
Results: 64% of ALA patients reported some level of improvement, with a level of maintenance of 68.75% one 
month after treatment. 27.6% of the placebo group also demonstrated some reduction in BMS symptoms. 
Conclusions: Long-term evolution and the intensity of symptoms are variables that reduce the probability of im-
provement with ALA treatment.
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Introduction
Burning mouth syndrome (BMS) is defined as a burning 
sensation in the oral mucosa with no clinical signs that 
could justify the syndrome. (1). The prevalence of BMS 
is 1-3% in developed countries (2), and occurs more fre-
quently in the middle-aged and the elderly population, 
especially women, with a 7:1 ratio. (2). BMS is consid-
ered a syndrome as it is frequently associated with two 
other symptoms: xerostomia and dysgeusia (2).
In 1989, Lamey and Lewis (3) clinically classified BMS 
into three different types: type I, symptoms are not 
present upon awakening but worsen during the day; 
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type II, symptoms are continuous throughout the day; 
type III, symptoms are intermittent. 
The precise aetiology of BMS is still unknown, yet 
multiple local and systemic factors have been reported 
(4). Local factors associated with BMS include: hy-
posalivation and/or xerostomia (10-66% of cases) (5-7), 
parafunctional habits (7), contact allergies (8), poorly 
fitting prostheses (9), Candida albicans infection (10), 
as well as smoking, alcohol, caffeine, and very hot or 
spicy foods. Systemic factors associated with BMS in-
clude: menopause (5), nutritional deficiencies (vitamin 
B group, iron and folic acid) (5), diabetes mellitus (espe-
cially type II) (5), hypothyroidism, as well as other sys-
temic factors, for example, a long-term pharmacologic 
treatment with antihypertensive drugs (11).
Regarding psychological factors, it is unclear whether 
these are the cause or the result of BMS. Even so, psy-
chological factors account for BMS symptoms in more 
than 50% of patients, and include chronic anxiety, de-
pression and cancerphobia (12), among others. 
Scala et al. (13) suggest differentiating secondary BMS, 
when there is a local or systemic condition, from idio-
pathic BMS when there are no other visible alterations. 
Recent studies suggest that neurological factors may be 
a possible cause of BMS. (14) It has been reported that 
alterations of the chorda tympani nerve can lead to lin-
gual nerve hyperfunction resulting in the appearance of 
hyperalgesia (15). Data has also shown increased levels 
of Nerve Growth Factor (NGF) and TRPV1 channels 
in patients with BMS, both involved in thermal hyper-
algesia (16).
Alpha lipoic acid (ALA) is a potent antioxidant that is 
produced naturally in the body. It can also be found in 
some natural foods, such as potatoes, tomatoes and spin-
ach. To date, ALA’s main contribution is to slow down 
cutaneous ageing (17). It regenerates and strengthens 
the effects of other biological antioxidants. ALA is an 
efficient chelating agent for catalyzing metals in the for-
mation of reactive oxygen species (ROS), acting against 
those that have already generated (18). ALA acts as a 
coenzyme in the production of energy (ATP), and im-
proves glucose metabolism. In addition, ALA seems to 
favour the production of nerve growth factor (NGF) and 
has been used in the treatment of diabetic neuropathy 
(17,19). 
There is no established treatment for BMS given its 
unknown aetiology. A possible neurological cause has 
been recently underscored. Based on this datum and the 
benefits of ALA in the treatment of diabetic neuropathy, 
there have been attempts to demonstrate the efficacy of 
ALA in the management of BMS. Nonetheless, the re-
sults obtained have not been conclusive due to the com-
plexity of the variables studied. 
The main objective of this study was to evaluate the ef-
ficacy of ALA over placebo in the management of BMS; 
as well as to determine the statistical significance of the 
outcome variables.
Material and Methods
A double-blind placebo-controlled study was conducted 
in 60 patients clinically diagnosed with BMS. The study 
took place at the Departament of Oral Medicine and 
Surgery, Universidad Complutense of Madrid, Spain. 
Diagnosis was made during the first screening phase. 
Patients underwent a detailed clinical evaluation and 
data collection sheets were completed.  
The study comprised patients over 18 years of age clini-
cally diagnosed with BMS who reported a history of 
continuous oral burning pain for more than 4 months 
with no clinical signs that could justify the syndrome 
(13). Patients agreed to participate in the study and 
signed the written consent. Exclusion criteria included: 
patients whose burning sensation could be related to lo-
cal alterations; patients with analytical alterations and 
uncontrolled systemic diseases; and patients treated 
with cisplatin, cyclophosphamide, gentamicin and ami-
kacin due to the possible interaction of ALA with this 
medication. Patients undergoing any type of BMS treat-
ment were also excluded from the study.  
After validating the inclusion criteria and obtaining 
the signed informed consent, patients were randomly 
allocated to one of the two different sequence groups: 
A (placebo) or B (product). The study product (group 
B) is ALA, Thioderm R capsules, (SesDerma, S.L. 
Rafelbunyol, Valencia, Spain). Placebo (group A) was a 
similar-looking product based on cellulose starch. This 
protocol was approved by the Ethical Committee of the 
Hospital Clínico San Carlos of Madrid. 
All patients were assessed for salivary flow rates, at rest 
and stimulated, complete blood count and biochemis-
try values, including ferritin, vitamin B12 and folic acid 
levels.
Treatment consisted of a dose of 600 mg/day of alpha 
lipoic acid administered in 3 capsules of 200 mg every 8 
hours for 2 months. All patients were assessed every 15 
days for changes in symptomatology using a visual ana-
log scale (VAS), as well as for the occurrence of side ef-
fects. According to VAS patients were grouped in: mild 
[0-3,4], moderate [3,5-6,4] and severe [6,5-10]. Changes 
in VAS results were achieved as: mild improvement with 
reduction in 50-75%; great improvement with more than 
75% reduction and curation when VAS was zero. When 
VAS result raised it was achieved as worsened. Patients 
were reassessed one month after treatment. 
Statistically significant differences between both groups 
were analysed using contingency tables and Pearson’s 
Chi-square test. In order to describe how the different 
variables may influence the results of the treatment, the 
logistic regression analysis was conducted independ-
ently for each of the groups.
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Results
60 Patients diagnosed with BMS were included in the 
study: 55 women (91.7%) and only 5 men (8.3%) with a 
median age of 62.13 years (range 36-86). We didn t´ find 
any alteration in any serological variables analyzed.
The evolution time of symptomatology varied between 
4 months and 20 years. The mean intensity of the symp-
toms evaluated by VAS (graduated from 0 to 10) was 
6.6 (range 2.5-10). 38 patients (63.3%) reported a burn-
ing sensation as the most common symptom, followed 
by stinging (12 patients, 20%). The rest reported itching 
and other symptoms. The tongue was the most affected 
site, yet 38 patients (63.3%) reported more than one site. 
According to Lamey and Lewis’s BMS classification, 38 
patients (63.3%) belonged to type I, 17 patients (28.3%) 
to type II, and only 5 patients (8.3%) to type III.
In addition to burning sensation, 10 patients (16.7%) 
reported dysgeusia, and 13 (21.7%) xerostomia. 24 pa-
tients (40%) reported having both symptoms at the same 
time. A reduction in both stimulated and unstimulated 
salivary flow was found in 25 patients (41.7%).
In our study, 20 patients (33.3%) associated the onset 
of their BMS symptoms with a dental treatment. 16 pa-
tients (26.7%) related BMS with personal and/or family 
issues. 
Regarding BMS and its association with systemic 
pathologies, 19 patients (31.7%) showed none, while 13 
(21.7%) had high blood pressure, and 8 (13.3%) hypothy-
roidism. 19 patients (31.7%) presented other pathologies 
as diabetes mellitus, osteoporosis, arthrosis and gas-
trointestinal alterations.
To assess level of depression we used the Beck Depres-
sion Inventory (BDI). BSI is the most widely used in-
strument for detecting depression the BDI–II consists of 
21 items to assess the intensity of depression in clinical 
and normal patients. Each item is a list of four state-
ments arranged in increasing severity about a particular 
symptom of depression.
59 patients filled out the questionnaire. 32 (54.2%) pa-
tients showed some level of depression.
Regarding the use of medication, in our study 53.3% 
of patients used some type of  psychotropic drug (anti-
depressants and/or anxiolytics), 25% antihypertensives 
(11.7%  ACE inhibitors, 8.3% beta-blockers, 3.3% diu-
retics and 1.7% ACE inhibitor +beta-blocker), 11.7% 
levothyroxine and 43.3% other medication (antacids, 
analgesics and antidiabetics).
60 patients agreed to participate in the study, but only 
54 completed the trial: 29 patients belonged to group A 
(placebo) and 25 to group B (ALA). Patients were reas-
sessed every 15 days after the beginning of the treat-
ment.  Final results were obtained after two months ac-
cording to the level of variation on VAS scored by the 
patient and the self-reported description.  
Since these are qualitative variables, results were 
analysed using contingency tables and Pearson’s Chi-
square test. Results were divided into three categories: 
improvement (slight improvement, decided improve-
ment and resolution), no change and worse. 
8 of the 29 patients treated with placebo showed some 
level of improvement (27.5%), 5 worsened  (17.2%) and 
16 experimented no change in symptomatology (55.2%). 
16 (64%) of the 25 patients treated with ALA improved, 
9 (36%) showed no changes, and none worsened. Statis-
tically significant differences between both groups were 
established when p<0.05 (p=0,009) was obtained from 
the Chi-square test. Comparing the ALA and placebo 
groups, it should be noted that none of the ALA patients 
reported worsening during the trial, and the possible 
placebo effect in BMS, given that 30% of the patients 
treated with placebo improved at the end of the treat-
ment. The results are summarized in table 1.
Patients were reassessed one month after treatment. 4 
of the 8 patients who had improved during treatment 
with placebo (Group A) reported a relapse of burning. 
5 (31.25%) of the 16 patients with signs of improvement 
during ALA treatment (Group B) worsened one month 
after treatment was concluded.
In order to describe how the different variables may in-
fluence the results of the treatment, the logistic regres-
sion analysis was conducted independently for each of 
the groups. The placebo group did not have statistical 
significance, yet the ALA group showed significant re-
sults. Consequently, patients without depression or with 
mild-moderate depression, experiencing low symptom 
intensity and an evolution time of less than a year are 
more likely to improve. However, patients undergoing 
antidepressant and/or anxiolytic therapy, who had se-
Treatment Response Results
Patients Improvement No change Worse Total
Total     A n 8 16 5    29 
%    27,6%        55,2%    17,2%  100,0% 
             B n                      16  9 0      25 
%    64,0%   36% ,0% 100,0% 
Total n                      24 25      5     54 
%  44,4%       46,3%    9,3% 100,0% 
Table 1. Results of treatment.
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vere symptoms and associated their onset with some den-
tal procedure, dysgeusia and xerostomia as well as burn-
ing, and an evolution time of more than 4 years, showed 
less likelihood of improving with ALA (Fig. 1).
Fig. 1. Influence of Variables in treatment response to ALA (% ). (Negative values indicate worse response to ALA).




Discussion
There are no definitive therapies for BMS (20). Accord-
ing to published data, ALA is reportedly one of the most 
effective drugs in the management of BMS. However, 
to date, there is no clear consensus (21).
Femiano et al. have published most of the studies that 
examine the efficacy of ALA in the management of 
BMS (22-26). They use a dose of 600mgr/day with a 
follow up around 30 days in their studies, as our study. 
Their results have been quite effective for ALA in order 
to improve symptoms, very similar in general compared 
with our results. There are some differences to consider 
that we point below.
In their first study (22), they carried out an open tri-
al of 42 patients to compare ALA treatment (600 mg/
day) over placebo. In the study group, none of the pa-
tients worsened, similar to our study. 24% presented no 
changes and 76% reported some level of improvement. 
However, statistical analysis was not conducted, the 
sample size was small, and treatment duration was only 
one month. 
Femiano and Scully (23) evaluated ALA at a dose of 600 
mg/day in a 60-patient double-blind placebo controlled 
study. 97% of the patients reported some improvement 
with ALA, 3% showed no changes in symptomatol-
ogy, and none of the patients reported worsening of 
symptoms. These results were statistically significant 
in favour of ALA. Similarly to our study, not a single 
patient treated with ALA worsened; but the results ob-
tained with ALA (97% improvement) were higher than 
our own results. We must also highlight the important 
placebo effect obtained (40%). 
In 2002, Femiano et al. (24) compared ALA with other 
products (Bethanechol 5mg/8 hours, Lactoperoxidase 
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and 3% Xylitol). Administration of ALA showed statis-
tically significant results.
Femiano et al. (25) in 2003 conducted an open trial of 
192 patients divided into four groups: one undergoing 
cognitive therapy (CT), one treated with ALA (600mg/
day), one combining CT and ALA, and one with pla-
cebo. The ALA group and the ALA + CT group showed 
statistically significant improvement compared to CT 
alone and the placebo group.
In 2004, Femiano et al. (26) studied the efficacy of ALA 
in patients treated with and without anxiolytics. Al-
though the latter group displayed more significant results, 
these were not statistically significant. In 2011, López-
D’Alessandro and Escovich verified the efficacy of ALA 
(600 mg/day) in conjunction with gamma-aminobutyric 
acid (GABA) over placebo over a two-month period. The 
combination ALA + GABA proved to be the most effec-
tive according to patients’ perceptions (27).
Other authors have used ALA in higher concentrations. 
In 2008, Carbone et al. (28) conducted a 60-patient 
double-blind study to evaluate the efficacy of pure ALA 
800 mg/day over ALA 800 mg/day supplemented with a 
vitamin complex, and in comparison with placebo. The 
3 groups showed a reduction in symptoms, but with no 
statistical significance. López-Jornet et al. (29) used the 
same concentration of ALA over placebo and equally 
found that both groups improved, yet with no statisti-
cally significant differences.
Finally, Cavalcanti et al. (30), in their crossover trial 
comparing the efficacy of ALA (600mg/day) over pla-
cebo, found a reduction in symptoms in both groups. 
The rate of this reduction was higher in the first month 
than in the second month of treatment.
ALA appears to have benefits in the management of 
BMS, yet the results supporting its efficacy is inconclu-
sive. Further studies, with a higher number of patients, 
are, therefore, needed.
Variables such as depression, long-term evolution and 
symptom intensity make it less likely for ALA patients 
to improve. This fact, together with the importance of 
the placebo effect, suggests the need to assess the psy-
chological and/or psychiatric implications that may re-
quire multidisciplinary treatments.
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